will blue cross blue shield cover glp 1 BCBSM pulling back on GLP-1 coverage florida blue glp 1 coverage

While both target similar mechanisms to aid weight loss, semaglutides extended-release formulation leads to more sustained effects and greater overall weight reduction

Also, the U.S Food and Drug Administration (FDA) is cracking down on compounded drugs, so their availability could change

Future outlook: what comes next for both compounds The peptide weight loss landscape is evolving rapidly, and both cagrilintide and retatrutide sit at the center of that evolution

Over time, the body develops some tolerance to the gastric slowing effect, so their gastric emptying delay is less acute (and thus they have milder postprandial effect relative to short-acting ones) ( [112] ) ( [113] )

"Malignant Peripheral Nerve Sheath TumorsA Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management"

The FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications in September 2025